Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838369 | 0.92 | POLB (0.38) | POLBCYP3A4ABL1RIN1 | |
| SCHEMBL835719 | 0.81 | POLB (0.46) | POLBABL1RIN1NR3C1NT5E | |
| SCHEMBL14066268 | 0.81 | POLB (0.41) | POLBABL1RIN1NT5EP2RY6 | |
| SCHEMBL1965642 | 0.80 | POLB (0.37) | POLBABL1RIN1NT5EP2RY6 | |
| SCHEMBL16350596 | 0.73 | POLB (0.40) | POLBABL1RIN1NT5EP2RY6 | |
| SCHEMBL22327455 | 0.73 | POLB (0.58) | POLBCYP3A4ABL1RIN1NT5E | |
| SCHEMBL25754094 | 0.73 | POLB (0.58) | POLBCYP3A4ABL1RIN1NT5E | |
| SCHEMBL20535901 | 0.73 | POLB (0.58) | POLBCYP3A4ABL1RIN1NT5E | |
| SCHEMBL14066269 | 0.71 | POLB (0.50) | POLBABL1RIN1NT5EP2RY6 | |
| SCHEMBL10699198 | 0.70 | POLB (0.58) | POLBCYP3A4ABL1RIN1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221140-A1 | 1-[2',3' -Dideoxy-3' C-(Hydroxymethyl) - Beta-D-Erythro-Pentofuranosyl] Cytosine Derivatives as Hiv | MEDIVIR AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1899352-A1 | 1- [2' , 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | MEDIVIR AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007006707-A1 | 1- [2' , 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221140-A1 | 1-[2',3' -Dideoxy-3' C-(Hydroxymethyl) - Beta-D-Erythro-Pentofuranosyl] Cytosine Derivatives as Hiv | NUDT1, TYMP, DPYD | POLB 14/4885CYP3A4 482/4885ABL1 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.